Exactech Investor Update

Helping surgeons worldwide make patients more mobile

Q1 • 2017

Investment Highlights

Targeting $47 billion

global biomedical device

market

Consistent long term

growth2x as fast as overall

market

Broad product portfolio

of innovative products

Robust product pipeline

expanding company’s

market

Highly experienced

orthopaedic management

team

Growing sales

organizationwith increasing rep

productivity

Proven track recordof creating long-term

profitable growth

2

Our Strategy

CUSTOMER INTIMACY

Innovation Channel

Development

Operational Excellence

3

Our Story

Surgeon founded Innovation to improve

patient outcomes

Surgeon input driven Collaborative relationship

with

sales force

Financial stability

4

A proven track record of growth

5

1985 1990 1994 1998 2002 2006 2010 2014 2017

$268M

First Knee Implant Sales

1994

Launched Internal Manufacturing

1998

Equinoxe® Shoulder Launch2

00

5

French Distributor Acquisition

2008

Vertical Supply Acquisitions

2010

Launching Vantage Ankle

& Truliant Knee Systems2017

Launched Three

Revision Systems2016

Launch of ExactechGPS®

CAS Technology Acquisition2014

250

200

150

100

50

0

RE

VE

NU

E I

N M

ILL

ION

S

YEAR

Source: OrthoWorld Orthopaedic Industry Annual Report April 2016 and company estimates

Targeting Highly Attractive Markets

Hip

2% Growth Rate

$7.0 BillionSales

6

Knee

4% Growth Rate

$8.5 BillionSales

Biologics

3% Growth Rate

$4.9 BillionSales

Extremities

8% Growth Rate

$2.0 BillionSales

ExactechGPS® KNEE HIP

EXTREMITIES ANKLE CEMENT/SPACERS

BIOLOGICS

2016 sales by segment based on 2016 SEC 10-K excluding divested spine business

2016 Sales by Segment ($ millions)

Broad Portfolio of Innovative Products

40%

11%

30%

19%

OTHER

$27.8

EXTREMITIES

$100.3HIP

$46.7

KNEE

$76.2

7

Equinoxe® Platform Shoulder

redefining intra-operative

flexibility, solving clinical

challenges surgeons face.

Extremities

Primary, Fracture, Reverse

Bone conserving glenoid options

Revision, Salvage and Tumor

solutions

Pipeline of strong clinical publications

ExactechGPS® Computer Assisted

Surgery System launching 2H17

Preserve Short Stem launching 2H17

8

VantageTM Ankle System

Developed by world-class team of

design surgeons. Full launch in 2017.

Extremities

9

Comprehensive total knee system

with excellent clinical results.

Knee

40-year evolved design

Multiple constraint options for primary &

revision knees with NCM poly

Exactech GPS® - Computer Assisted

Surgery System

Optetrak Logic® CC revision

10

Truliant® high performance, comprehensive system addresses primary and revision knee replacement.

Knee

Supports surgeon goals for reproducible

clinical outcomes

Wide array of options for improved

versatility

Modified implant design to accommodate

various patient anatomy

Intuitive instrumentation with visual,

audible and tactile feedback for

intraoperative adjustability

Expanded Exactech GPS® computer-

assisted surgery applications

Clinical introduction in 2H17 11

Primary, Fracture, Revision

Tapered Wedge and Neck Preserving Stem designs

Direct Anterior Approach instrumentation

Acetabular cup with InteGrip® technology

Alteon® Monobloc Revision System

HipAddressing the major

philosophies of THA

12

Surgeon maintains operating control

Reproducible outcomes - Real-time feedback

Competitive marketing edge for hospitals

Applications for shoulder, primary and revision knee

ExactechGPS®

Surgeon controlled, computer-assisted technology for reproducibility in total joint arthroplasty.

13

Innovative, clinically effective

biomaterials

Biologics

Optecure® Allograft DBM products

Accelerate® Cell Therapy

OssilixTM Calcium Phosphate Cement

ReveilleTM Cartilage Processor

14

Safety, simplicity and efficacy

Cement, Spacer

and Implant

Removal

Cemex® bone cement

InterSpace® preformed hip, knee and

shoulder spacers with High Release

technology

AcuDriver® Automated Osteotome

System

15

Exactech Manufacturing

Manufacturing

in U.S.

65% Internal

Implant Mfg

Lean initiatives in

manufacturing and

entire company.

16

GLOBAL

OFFICES/SUBSIDIARIES

DISTRIBUTORSMANUFACTURING &

HEADQUARTERS

Our Reach

US

Network of independent sales agencies (35+)

Independent sales representatives (300+)

Managed by corporate regional vice presidents

OUS

Network of independent distributors and wholly-owned subsidiaries

Direct operations in: UK, Spain, Germany, France, Japan, China, Australia

17

Financial Trends

224

237

248242

257

268

160

220

280

12 13 14 15 16 17G

Revenues ($ Mil)

FY Guidance $264-272MM; +6-9% Proforma*

0.96

1.12

1.18

1.04

1.18

1.28

0.80

1.00

1.20

1.40

12 13 14 15 16* 17G

Earnings Per Share

FY’17 Guidance $1.24-1.32

* Non-GAAP Revenue Growth and Diluted EPS Estimates excluding impact of

impairment/restructuring announced 4Q16

18

Summary Financial Data

$ and shares in millions Dec-16 Mar-17

Cash $13.1 $11.2

Debt $20.0 $16.0

Shareholders’ Equity $234.2 $240.3

Common Shares Outstanding (1) 14.3

Market Value (2) $433.4

19

(1) Per 5.3.17 1Q17 10-Q filing

(2) Based on Market Closing Price $30.20 5.9.17

Why Exactech?

Understanding of market needs and

opportunities

Major new product introductions

Sales channel opportunities

Proven financial performance and

corporate stability

20

Thank you.

This presentation contains various forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934 which represent the company’s expectations or beliefs concerning future events. These forward lookingstatements are further qualified by important factors that could cause actual results to differ materially from those in the forward lookingstatements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to producecomponents on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of governmentregulation, including without limitation an ongoing investigation by the U.S. Department of Justice of various practices within the orthopaedicindustry, as well as other risks and uncertainties including those described in the company’s filings with the Securities and Exchange Commission.You should carefully consider these risks before making a decision to invest in our securities. Results actually achieved may differ materially fromexpected results included in these statements.